A Phase 1 interventional study of Sitagliptin 100 mg and Saxagliptin 5 mg in Type 2 Diabetes Mellitus, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2017-05-30.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 — 3 open to participants now, 5 under way, none of them phase 3. sitagliptin · Diabetes Mellitus, Type 2.
Among the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, this one is the 160th largest by enrollment of the 197 interventional ones that give a count, is one of 16 that started in 2012, is one of 23 in phase 1, and was the 116th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →3 of the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:
Beijing Chao Yang Hospital · Sites in China
Ages 18–65
Bahria University · Sites in Pakistan
Ages 30–55
Yonsei University · Sites in Korea, Republic of
Ages 19–75
By country, each count listing its studies:
sitagliptin: first FDA approval 2006 (JANUVIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
198 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 11 · Phase 3 74 · Phase 4 68
First in 2003; this study’s year is marked. 16 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 22 is below the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 102 across the 197 interventional studies. Of the 172 that completed or were terminated, 117 (68%) have results posted.
This tab as a report to print or save as PDF → With an account.
103 of 198 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
181 studies in Diabetes Mellitus, Type 2 by Merck & Co., Inc: none open now, none under way, none of them phase 3. Of 181 finished, 150 (83%) have results posted.
Among the 181 studies in Diabetes Mellitus, Type 2 by Merck & Co., Inc, this one is the 148th largest by enrollment of the 170 interventional ones that give a count, is one of 20 that started in 2012, is one of 55 in phase 1, and was the 128th registered.
Merck & Co., Inc’s Diabetes Mellitus, Type 2 studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Merck & Co., Inc’s 181 in Diabetes Mellitus, Type 2:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A five-period crossover study to assess and compare the trough dipeptidyl peptidase IV (DPP-4) inhibition at 24-hours following the final morning dose for sitagliptin, saxagliptin and vildagliptin after 5 days of once daily dosing and vildagliptin after 5 days of twice daily dosing in participants with T2DM. The primary hypothesis is that following multiple daily dose administration to achieve steady-state drug concentrations, 100-mg sitagliptin will demonstrate greater DPP-4 inhibition at 24-hours after the final dose compared to 5-mg saxagliptin and 50-mg vildagliptin (once daily administration) in participants with T2DM. Each participant will receive all 5 treatments in randomized order. There will be a washout interval of at least 10 days between the last dose of study drug in one period and the first dose of study drug in the following period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Sitagliptin 100 mg in Period 1 followed by saxagliptin 5 mg in Period 2 followed by vildagliptin 50 mg BID in Period 3 followed by placebo in Period 4 followed by vildagliptin 50 mg in Period 5
Drug: Sitagliptin 100 mg · Drug: Saxagliptin 5 mg · Drug: Vildagliptin 50 mg · Drug: Vildagliptin 50 mg BID · Drug: Placebo
Saxagliptin 5 mg in Period 1 followed by vildagliptin 50 mg in Period 2 followed by placebo in Period 3 followed by sitagliptin 100 mg in Period 4 followed by vildagliptin 50 mg BID in Period 5
Drug: Sitagliptin 100 mg · Drug: Saxagliptin 5 mg · Drug: Vildagliptin 50 mg · Drug: Vildagliptin 50 mg BID · Drug: Placebo
Vildagliptin 50 mg in Period 1 followed by vildagliptin 50 mg BID in Period 2 followed by sitagliptin 100 mg in Period 3 followed by saxagliptin 5 mg in Period 4 followed by placebo in Period 5
Drug: Sitagliptin 100 mg · Drug: Saxagliptin 5 mg · Drug: Vildagliptin 50 mg · Drug: Vildagliptin 50 mg BID · Drug: Placebo
Vildagliptin 50 mg BID in Period 1 followed by placebo in Period 2 followed by saxagliptin 5 mg in Period 3 followed by vildagliptin 50 mg in Period 4 followed by sitagliptin 100 mg in Period 5
Drug: Sitagliptin 100 mg · Drug: Saxagliptin 5 mg · Drug: Vildagliptin 50 mg · Drug: Vildagliptin 50 mg BID · Drug: Placebo
Placebo in Period 1 followed by sitagliptin 100 mg in Period 2 followed by vildagliptin 50 mg in Period 3 followed by vildagliptin 50 mg BID in Period 4 followed by saxagliptin 5 mg in Period 5
Drug: Sitagliptin 100 mg · Drug: Saxagliptin 5 mg · Drug: Vildagliptin 50 mg · Drug: Vildagliptin 50 mg BID · Drug: Placebo
Sitagliptin 100 mg in Period 1 followed by vildagliptin 50 mg in Period 2 followed by saxagliptin 5 mg in Period 3 followed by placebo in Period 4 followed by vildagliptin 50 mg BID in Period 5
Drug: Sitagliptin 100 mg · Drug: Saxagliptin 5 mg · Drug: Vildagliptin 50 mg · Drug: Vildagliptin 50 mg BID · Drug: Placebo
Saxagliptin 5 mg in Period 1 followed by vildagliptin 50 mg BID in Period 2 followed by vildagliptin 50 mg in Period 3 followed by sitagliptin 100 mg in Period 4 followed by placebo in Period 5
Drug: Sitagliptin 100 mg · Drug: Saxagliptin 5 mg · Drug: Vildagliptin 50 mg · Drug: Vildagliptin 50 mg BID · Drug: Placebo
Vildagliptin 50 mg in Period 1 followed by placebo in Period 2 followed by vildagliptin 50 mg BID in Period 3 followed by saxagliptin 5 mg in Period 4 followed by sitagliptin 100 mg in Period 5
Drug: Sitagliptin 100 mg · Drug: Saxagliptin 5 mg · Drug: Vildagliptin 50 mg · Drug: Vildagliptin 50 mg BID · Drug: Placebo
Vildagliptin 50 mg BID in Period 1 followed by sitagliptin 100 mg in Period 2 followed by placebo in Period 3 followed by vildagliptin 50 mg in Period 4 followed by saxagliptin 5 mg in Period 5
Drug: Sitagliptin 100 mg · Drug: Saxagliptin 5 mg · Drug: Vildagliptin 50 mg · Drug: Vildagliptin 50 mg BID · Drug: Placebo
Placebo in Period 1 followed by saxagliptin 5 mg in Period 2 followed by sitagliptin 100 mg in Period 3 followed by vildagliptin 50 mg BID in Period 4 followed by vildagliptin 50 mg in Period 5
Drug: Sitagliptin 100 mg · Drug: Saxagliptin 5 mg · Drug: Vildagliptin 50 mg · Drug: Vildagliptin 50 mg BID · Drug: Placebo
Sitagliptin 100 mg: one sitagliptin 100 mg tablet once daily in the morning following a fast of at least approximately 8 hours on Days 1 through 5 in one out of five treatment periods.
Also known as: Januvia™
Saxagliptin 5 mg: one saxagliptin 5 mg tablet once daily in the morning following a fast of at least approximately 8 hours on Days 1 through 5 in one out of five treatment periods.
Also known as: Onglyza™
Vildagliptin 50 mg: one vildagliptin 50 mg tablet once daily in the morning following a fast of at least approximately 8 hours on Days 1 through 5 in one out of five treatment periods.
Also known as: Galvus™
Vildagliptin 50 mg BID: one vildagliptin 50 mg tablet BID (twice daily), once in the morning following a fast of at least approximately 8 hours and once in the evening on Days 1 through 5 in one out of five treatment periods.
Also known as: Galvus™
Placebo: one placebo for sitagliptin tablet once daily in the morning following a fast of at least approximately 8 hours on Days 1 through 5 in one out of five treatment periods.
Percent Inhibition of Dipeptidyl Peptidase IV (DPP-4) Activity at Trough
Percent inhibition of DPP-4 activity at 24 hours after the Day 5 morning dose (i.e., at trough) was determined by analysis of blood samples collected from the study participants.
Time frame: 24 hours following the final morning dose on Day 5
Pharmacokinetic Analysis: Area Under the Curve 0-24 Hours (AUC 0-24hr)
AUC 0-24hr is the area under the plasma drug concentration-time curve calculated for the 24 hour interval after the Day 5 morning dose.
Time frame: Predose (0 Hours) and 0.5, 1, 2, 4, 8, 12, 13 (vildagliptin 50 mg BID only), 14 (vildagliptin 50 mg BID only), 16, 20 and 24 hours after the morning dose on Day 5
Pharmacokinetic Analysis: Area Under the Curve 0-12 Hours (AUC 0-12hr) for Vildagliptin 50 mg BID
AUC 0-12hr is the area under the plasma drug concentration-time curve calculated for the 12 hour interval after the Day 5 morning dose for the vildagliptin 50 mg BID dose only.
Time frame: Predose (0 hours) and 0.5, 1, 2, 4, 8 and 12 hours after the morning dose on Day 5
Pharmacokinetic Analysis: Peak Plasma Drug Concentration (Cmax)
Measurement of the peak plasma drug concentration following the Day 5 morning dose.
Time frame: Predose (0 hours) and 0.5, 1, 2, 4, 8, 12, 13 (vildagliptin 50 mg BID only), 14 (vildagliptin 50 mg BID only), 16, 20, 24, 36, 48 and 96 hours after the morning dose on Day 5
Pharmacokinetic Analysis: Time to the Peak Plasma Drug Concentration (Tmax)
Measurement of the time to the peak plasma drug concentration following the Day 5 morning dose.
Time frame: Predose (0 hours) and 0.5, 1, 2, 4, 8, 12, 13 (vildagliptin 50 mg BID only), 14 (vildagliptin 50 mg BID only), 16, 20, 24, 36, 48 and 96 hours after the morning dose on Day 5
Each treatment sequence started with 2 participants in Period 1. In addition, there were 2 replacement participants; in treatment sequence 5, a participant who discontinued after period 1 (placebo treatment) was replaced and in treatment sequence 7, a participant who discontinued during period 1 (saxagliptin treatment) was replaced.
| Milestone | Treatment Sequence 1 | Treatment Sequence 2 | Treatment Sequence 3 | Treatment Sequence 4 | Treatment Sequence 5 | Treatment Sequence 6 | Treatment Sequence 7 | Treatment Sequence 8 | Treatment Sequence 9 | Treatment Sequence 10 |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 2 | 2 | 2 | 2 | 3 | 2 | 3 | 2 | 2 | 2 |
| Completed | 2 | 2 | 2 | 2 | 3 | 2 | 2 | 2 | 2 | 2 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Milestone | Treatment Sequence 1 | Treatment Sequence 2 | Treatment Sequence 3 | Treatment Sequence 4 | Treatment Sequence 5 | Treatment Sequence 6 | Treatment Sequence 7 | Treatment Sequence 8 | Treatment Sequence 9 | Treatment Sequence 10 |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 2 | 2 | 2 | 2 | 3 | 2 | 2 | 2 | 2 | 2 |
| Completed | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| Not completed | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Treatment Sequence 1 | Treatment Sequence 2 | Treatment Sequence 3 | Treatment Sequence 4 | Treatment Sequence 5 | Treatment Sequence 6 | Treatment Sequence 7 | Treatment Sequence 8 | Treatment Sequence 9 | Treatment Sequence 10 |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| Completed | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Treatment Sequence 1 | Treatment Sequence 2 | Treatment Sequence 3 | Treatment Sequence 4 | Treatment Sequence 5 | Treatment Sequence 6 | Treatment Sequence 7 | Treatment Sequence 8 | Treatment Sequence 9 | Treatment Sequence 10 |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| Completed | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Treatment Sequence 1 | Treatment Sequence 2 | Treatment Sequence 3 | Treatment Sequence 4 | Treatment Sequence 5 | Treatment Sequence 6 | Treatment Sequence 7 | Treatment Sequence 8 | Treatment Sequence 9 | Treatment Sequence 10 |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| Completed | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Treatment Sequence 1 | Treatment Sequence 2 | Treatment Sequence 3 | Treatment Sequence 4 | Treatment Sequence 5 | Treatment Sequence 6 | Treatment Sequence 7 | Treatment Sequence 8 | Treatment Sequence 9 | Treatment Sequence 10 |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| Completed | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Treatment Sequence 1 | Treatment Sequence 2 | Treatment Sequence 3 | Treatment Sequence 4 | Treatment Sequence 5 | Treatment Sequence 6 | Treatment Sequence 7 | Treatment Sequence 8 | Treatment Sequence 9 | Treatment Sequence 10 |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| Completed | 1 | 2 | 2 | 2 | 2 | 1 | 2 | 2 | 2 | 1 |
| Not completed | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
| Withdrew: Physician decision | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
| Milestone | Treatment Sequence 1 | Treatment Sequence 2 | Treatment Sequence 3 | Treatment Sequence 4 | Treatment Sequence 5 | Treatment Sequence 6 | Treatment Sequence 7 | Treatment Sequence 8 | Treatment Sequence 9 | Treatment Sequence 10 |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 1 | 2 | 2 | 2 | 2 | 1 | 2 | 2 | 2 | 1 |
| Completed | 1 | 2 | 2 | 2 | 2 | 1 | 2 | 2 | 2 | 1 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Treatment Sequence 1 | Treatment Sequence 2 | Treatment Sequence 3 | Treatment Sequence 4 | Treatment Sequence 5 | Treatment Sequence 6 | Treatment Sequence 7 | Treatment Sequence 8 | Treatment Sequence 9 | Treatment Sequence 10 |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 1 | 2 | 2 | 2 | 2 | 1 | 2 | 2 | 2 | 1 |
| Completed | 1 | 2 | 2 | 2 | 2 | 1 | 2 | 2 | 2 | 1 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Percent inhibition of DPP-4 activity at 24 hours after the Day 5 morning dose (i.e., at trough) was determined by analysis of blood samples collected from the study participants.
| Percent inhibition | Sitagliptin 100 mg | Saxagliptin 5 mg | Vildagliptin 50 mg | Vildagliptin 50 mg BID | Placebo |
|---|---|---|---|---|---|
| Percent Inhibition of Dipeptidyl Peptidase IV (DPP-4) Activity at Trough | 91.73 (91.37 to 92.08) | 73.50 (66.56 to 79.00) | 28.88 (17.90 to 38.38) | 90.63 (88.93 to 92.06) | 3.49 (-0.66 to 7.48) |
AUC 0-24hr is the area under the plasma drug concentration-time curve calculated for the 24 hour interval after the Day 5 morning dose.
| nM*hr | Sitagliptin 100 mg | Saxagliptin 5 mg | Vildagliptin 50 mg | Vildagliptin 50 mg BID |
|---|---|---|---|---|
| Pharmacokinetic Analysis: Area Under the Curve 0-24 Hours (AUC 0-24hr) | 7070 ± 25.1 | 370 ± 25 | 3100 ± 27 | 6600 ± 26.3 |
AUC 0-12hr is the area under the plasma drug concentration-time curve calculated for the 12 hour interval after the Day 5 morning dose for the vildagliptin 50 mg BID dose only.
| nM*hr | Vildagliptin 50 mg BID |
|---|---|
| Pharmacokinetic Analysis: Area Under the Curve 0-12 Hours (AUC 0-12hr) for Vildagliptin 50 mg BID | 3720 ± 28.9 |
Measurement of the peak plasma drug concentration following the Day 5 morning dose.
| nM | Sitagliptin 100 mg | Saxagliptin 5 mg | Vildagliptin 50 mg | Vildagliptin 50 mg BID |
|---|---|---|---|---|
| Pharmacokinetic Analysis: Peak Plasma Drug Concentration (Cmax) | 724 ± 31.3 | 88.8 ± 25.2 | 586 ± 37 | 759 ± 34.7 |
Measurement of the time to the peak plasma drug concentration following the Day 5 morning dose.
| hr | Sitagliptin 100 mg | Saxagliptin 5 mg | Vildagliptin 50 mg | Vildagliptin 50 mg BID |
|---|---|---|---|---|
| Pharmacokinetic Analysis: Time to the Peak Plasma Drug Concentration (Tmax) | 4 (0.5 to 8) | 1 (0.5 to 2) | 1 (0.5 to 8) | 1 (0.5 to 4) |
Collected over Through approximately 14 days following the last dose of study drug in Period 5. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Sitagliptin 100 mg | — | 0/20 (0%) | 1/20 (5%) |
| Saxagliptin 5 mg | — | 0/21 (0%) | 4/21 (19%) |
| Vildagliptin 50 mg | — | 0/18 (0%) | 1/18 (5.6%) |
| Vildagliptin 50 mg BID | — | 0/19 (0%) | 1/19 (5.3%) |
| Placebo | — | 0/21 (0%) | 0/21 (0%) |
| Event | Sitagliptin 100 mg | Saxagliptin 5 mg | Vildagliptin 50 mg | Vildagliptin 50 mg BID | Placebo |
|---|---|---|---|---|---|
| InfluenzaInfections and infestations | 0/20 | 2/21 | 0/18 | 0/19 | 0/21 |
| HeadacheNervous system disorders | 1/20 | 2/21 | 1/18 | 1/19 | 0/21 |
| Age, Categorical(Participants) | All Enrolled Participants |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 22 |
| >=65 years | 0 |
| Sex: Female, Male(Participants) | All Enrolled Participants |
|---|---|
| Female | 12 |
| Male | 10 |
No study locations are listed for this record.
Plan to share: Yes — http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf http://engagezone.msd.com/ds_documentation.php
Ran from Jun 2012 to primary completion in Dec 2012, 5 months.
Results were first posted in Jan 2014, 1 year 1 month after primary completion.
Of 453 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 11. This study's 5 months is close to that.
Counting every sponsor, half of 515 studies reached it within 6 months; a quarter within 2 and three quarters within 14.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Sitagliptin · Saxagliptin · Vildagliptin